Overview of the Orphan Diseases and Drugs Space in Sub-Saharan Africa

NEW YORK, May 29, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Overview of the Orphan Diseases and Drugs Space in Sub-Saharan Africa

http://www.reportlinker.com/p0868600/Overview-of-the-Orphan-Diseases-and-Drugs-Space-in-Sub-Saharan-Africa.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Drug_and_Medication

Research was carried out on the orphan disease and related drug space in Sub-Saharan Africa with emphasis on 5 countries, namely, Ghana, Nigeria, Uganda, Kenya and Tanzania. An analysis into the systems, treatment regimes and organisation and company involvement and their interrelations was carried out. Each country's status, with respect to these analyses results, was ascertained. Market dynamics, including challenges, drivers and restraints, were also identified along with potential involvement opportunities.

TABLE OF CONTENTS

Research Aim and Objectives Slide 17

Research Scope, Definitions and Exchange Rates Slide 19

Research Methodology Slide 23

Orphan Drugs and Diseases in Sub-Saharan Africa—An Introduction Slide 25

Definition of an Orphan Disease Slide 26

Neglected Tropical Diseases—An Overview Slide 27

Rare Diseases—An Overview Slide 28

Awareness and Prevalence of Neglected Tropical Diseases in the Developing World Slide 29

Global Distribution of Neglected Diseases Slide 30

Consequences of NTDs at the Personal and Societal Levels Slide 31

Measuring the Impact of NTDs Slide 32

Three Policy Documents that Initiated Pro-active Awareness Slide 34

Millennium Development Goals (MDGs) Slide 35

Role of the FDA in Neglected Tropical Diseases Slide 36

Neglected Diseases in Sub-Saharan Africa Slide 37

Orphan Diseases—Top 11 NTDs in Sub-Saharan Africa Slide 38

Orphan Drug and Program Overview Slide 42

A Program Process Outline Slide 43

Organization Involvement in Instituting a Drug Implementation Program Slide 44

Key Program Initiatives and Associated Drugs Slide 45

Integrated Control and Mass Drug Administration Slide 46

A Solution to Drug Development Costs Slide 50

Public-Private Partnerships (PPPs) Slide 51

Latest Pharmaceutical Pledges Slide 54

Programme Challenges, Drivers and Restraints Slide 57

Country Analysis: Ghana Slide 71

Country Analysis: Nigeria Slide 81

Country Analysis: Uganda Slide 89

Country Analysis: Kenya Slide 98

Country Analysis: Tanzania Slide 105

Conclusions Slide 112

Country Implementation Comparison Slide 114

Appendix Slide 115

About Frost & Sullivan Slide 140

List of Figures

Orphan Diseases and Drugs: Top 11 Neglected Diseases, Sub-Saharan Africa, 2010 Slide 13 Orphan Diseases and Drugs: Exchange Rates, Sub-Saharan Africa, 2011 Slide 22 Orphan Diseases and Drugs: Disease Burden (DALYs) Resulting from the NTDs, Sub-Saharan Africa, 2010 Slide 32 Orphan Diseases and Drugs: FDA Activities Related to Neglected Tropical Diseases, Sub-Saharan Africa, 2010 Slide 36 Orphan Diseases and Drugs: The Top 11 Neglected Tropical Diseases and Their Etiologic Agents, Sub-Saharan Africa, 2010 Slide 38 Orphan Diseases and Drugs: The Top 11 NTDs, Common tests, Current Treatments and Notes for Opportunities, Sub-Saharan Africa, 2010 Slide 39 Orphan Diseases and Drugs: Overview of the Top 8 Neglected Diseases and Associated Treatments, Sub-Saharan Africa, 2010 Slide 45 Orphan Diseases and Drugs: Overview of 5 Neglected Tropical Diseases and Administration Strategies, Sub-Saharan Africa, 2010 Slide 48 Orphan Diseases and Drugs: Details Pertaining to the Major Drugs Used in the Treatment of Neglected Tropical Diseases, Sub-Saharan Africa, 2010 Slide 49 Orphan Diseases and Drugs: The Latest Contributions to NTDs from the Pharmaceutical Industry, Sub-Saharan Africa, 2010 Slide 54 Orphan Diseases and Drugs: Impact of Top Six Programme Challenges, Sub-Saharan Africa, 2011-2018 Slide 57 Orphan Diseases and Drugs: Programme Drivers Ranked in Order of Impact, Sub-Saharan Africa, 2011-2018 Slide 64 Orphan Diseases and Drugs: Programme Restraints Ranked in Order of Impact, Sub-Saharan Africa, 2011-2018 Slide 67 Orphan Diseases and Drugs: Mortality and Burden of Disease, Ghana, 2009 Slide 74 Orphan Diseases and Drugs: Health Facilities, Ghana, 2007 Slide 75 Orphan Diseases and Drugs: Healthcare Financing, Ghana, 2009 Slide 76 Orphan Diseases and Drugs: Chemotherapy Requirements for the Population, Ghana, 2008 Slide 77Orphan Diseases and Drugs: Situation Analysis of Preventive Chemotherapy Diseases, Ghana, 2008 Slide 77Orphan Diseases and Drugs: Preventive Chemotherapy Implementation, Ghana, 2009 Slide 78Orphan Diseases and Drugs: USAID's MDA Five Year Plan, Ghana, 2006-2011 Slide 79Orphan Diseases and Drugs: Drug Sources, Quantities and Delivery Dates, Ghana, 2010 Slide 80Orphan Diseases and Drugs: Mortality and Burden of Disease, Nigeria, 2009 Slide 84Orphan Diseases and Drugs: Number of Healthcare Providers, Nigeria, 2007 Slide 85Orphan Diseases and Drugs: Healthcare Financing, Nigeria, 2009 Slide 86Orphan Diseases and Drugs: Health Facilities, Nigeria, 2007 Slide 86Orphan Diseases and Drugs: Chemotherapy Requirements for the Population, Nigeria, 2008 Slide 87Orphan Diseases and Drugs: Situation Analysis of Preventive Chemotherapy Diseases, Nigeria, 2008 Slide 87Orphan Diseases and Drugs: Preventive Chemotherapy Implementation, Nigeria, 2009 Slide 88Orphan Diseases and Drugs: Number of Health Facilities by Ownership, Uganda, 2009 Slide 92Orphan Diseases and Drugs: Public Healthcare Financing, Uganda, 2009 Slide 93Orphan Diseases and Drugs: Chemotherapy Requirements for the Population, Uganda, 2008 Slide 94Orphan Diseases and Drugs: Situation Analysis of Preventive Chemotherapy Diseases, Uganda, 2008 Slide 94Orphan Diseases and Drugs: Preventive Chemotherapy Implementation, Uganda, 2009 Slide 95Orphan Diseases and Drugs: USAID's MDA Five Year Plan, Uganda, 2006-2011 Slide 96Orphan Diseases and Drugs: MDA Targets, Uganda, 2006-2011 Slide 96Orphan Diseases and Drugs: Drug Estimates and Logistics, Uganda, 2010 Slide 97Orphan Diseases and Drugs: Healthcare Financing, Kenya, 2009 Slide 102Orphan Diseases and Drugs: Chemotherapy Requirements for the Population, Kenya, 2008 Slide 103 Orphan Diseases and Drugs: Situation Analysis of Preventive Chemotherapy Diseases, Kenya, 2008 Slide 103 Orphan Diseases and Drugs: Preventive Chemotherapy Implementation, Kenya, 2009 Slide 104 Orphan Diseases and Drugs: Health Facilities, Tanzania, 2009 Slide 108 Orphan Diseases and Drugs: Public Health Staff, Tanzania, 2009 Slide 108 Orphan Diseases and Drugs: Healthcare Financing, Tanzania, 2009 Slide 109 Orphan Diseases and Drugs: Chemotherapy Requirements for the Population, Tanzania, 2008 Slide 110 Orphan Diseases and Drugs: Situation Analysis of Preventive Chemotherapy Diseases, Tanzania, 2008 Slide 110 Orphan Diseases and Drugs: Preventive Chemotherapy Implementation, Tanzania, 2009 Slide 111

List of Charts

Orphan Diseases and Drugs: The Percentage Prevalence of Five Neglected Diseases Compared to the Global Prevalence, 2010 Slide 13

Orphan Diseases and Drugs: The Disease Burden of NTDs Compared with the "Big Three" in Disability-adjusted Life Years or DALYs, Sub-Saharan Africa, 2009 Slide 14

Orphan Diseases and Drugs: Geographic Overlap of the Neglected Tropical Diseases, Global, 2010 Slide 27

Orphan Diseases and Drugs: Current and Predicted Growth in the Orphan Drug and Biological Drug Markets,

Global, 2006-2014 Slide 28

Orphan Diseases and Drugs: Percent Breakdown of the Top Four Neglected Tropical Diseases, Global, 2010 Slide 29

Orphan Diseases and Drugs: Most Prevalent Neglected Tropical Diseases, Global, Sub-Saharan Africa, Asia and

Latin America, 2010 Slide 30

Orphan Diseases and Drugs: Projected DALYs by Cause, Africa and Global, Baseline Scenario 2015 Slide 33

Orphan Diseases and Drugs: The Disease Burden of NTDs Compared with the "Big Three" in Disability-Adjusted Life Years or

DALYs, Sub-Saharan Africa, 2009 Slide 33

Orphan Diseases and Drugs: A Comparison of the Top 7 Most Prevalent Neglected Tropical Diseases, Sub-Saharan Africa and Global, 2009 Slide 38

Orphan Diseases and Drugs: Organisation Involvement Overview, Sub-Saharan Africa, 2010 Slide 44

To order this report:Drug and Medication Industry: Overview of the Orphan Diseases and Drugs Space in Sub-Saharan Africa

More  Market Research Report

Check our  Industry Analysis and Insights

Nicolas Bombourg

Reportlinker

Email: [email protected]

US: (805)652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker